Deutsch  |  English   

GenoType PAI-1

Your test system for the definitive detection of two polymorphisms in the PAI-1 gene

Every year in Germany, several thousand people die from the consequences of vessel occlusions, such as a heart attack or pulmonary embolism.
Risk factors for such a vessel occlusion include, for example, increased blood lipid values, and also the body’s own substances can promote the development of occlusions. Thus an increase in the plasminogen activator inhibitor type 1 (PAI-1) level is also a risk factor for venous and arterial thrombosis PAI-1 is responsible for inhibiting two proteins which play an important role in the re-dissolution of a thrombus. An increased PAI-1 level thus leads to a greater inhibition of the proteins and therefore to a slower breakdown of the blood clot.
Two polymorphisms in the PAI-1 gene are associated with an increased PAI-1 level. Through insertion or deletion, either 4 or 5 guanine nucleotides may be present at position –675. If the 4G allele is present, there is an increased risk for venous thrombosis, primarily if additional thrombosis-related mutations are also present. In addition, for this genotype, an increased risk of myocardial infarcts and early miscarriages has also been established. Furthermore, the A-844G polymorphism in the PAI-1 gene is relevant. If the AA genotype is present, the risk of venous thrombosis is increased for Factor V Leiden carriers.
Since there is an increased risk of thrombosis in connection with thrombosis-related mutations, testing of the PAI-1 polymorphisms should be performed to assess individual thrombosis risk. In addition, it is useful to test patients with coronary artery disease and high-risk pregnancies.

Our GenoType PAI-1 test system allows you to detect with certainty the two polymorphisms and thus assess individual thrombosis risk.

reaction zones GenoType PAI-1

Your benefits with GenoType PAI-1

  • No limitation: the PAI-1 level in the blood is affected by various factors, such as, for example, glucose or also insulin. Therefore, biochemical methods only allow documentation of the actual situation. An increased PAI-1 level over the long term, by contrast, is only conditionally detected. Testing the genetic foundation is therefore of use and is recommended.
  • Definite result: if the test is not processed under optimal conditions, this will be indicated by an internal control.
  • Simple evaluation: using an evaluation template, the test result can be read rapidly and clearly.

At a glance
Molecular genetic assay for analysis of the -675 4G/5G and A-844G polymorphisms of the PAI-1 gene

Starting material:
EDTA/Citrate blood

DNA Isolation:
GENO•CARD or
GenoType DNA Isolation Kit

Order number: 
12 tests  No. 222
96 tests  No. 22296

Technology:
DNASTRIP technology

Downloads:
Instruction for Use (IFU)
Flyer
Evaluation sheet
Overview equipment programs

Information request:
Enquiry